The FDA granted accelerated approval for Truvada, a fixed-dose combination of Gilead Sciences Inc.'s anti-HIV medications Emtriva and Viread. (BioWorld Today)

Gilead's Combination HIV Drug, Truvada, Wins FDA Clearance

Aug. 4, 2004

By Kim Coghill

The FDA granted accelerated approval for Truvada, a fixed-dose combination of Gilead Sciences Inc.'s anti-HIV medications Emtriva and Viread. (BioWorld Today)

Today's news in brief
BioWorld
BioWorld briefs for March 6, 2026.
CROI 2026 highlights depression and cognitive vulnerability in HIV
BioWorld
The effects of aging pose an additional challenge for people with HIV due to the neurological and psychological consequences that persist despite antiretroviral...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 3, 2026
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
University of Southern California reports new MAPT aggregation inhibitors
BioWorld Science
The University of Southern California has identified (2-oxo-2H-chromen-3-yl) scaffold-based carboxamide analogues acting as potent microtubule-associated protein...